Experimental CAR T-Cell therapy takes on recurrent brain cancer
NCT ID NCT07496073
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein called CD70. The study will enroll 30 participants to check if the treatment is safe and to get an early look at whether it can shrink tumors or help people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CHT101 (a type of immune cell therapy called CAR T-cells, targeting CD70 on tumor cells)
- What this could lead to
- If successful, this could point toward a new treatment option for people with aggressive brain tumors that have come back or worsened after standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, so it is primarily testing safety. The therapy may not shrink tumors or improve survival, and there could be serious side effects from the immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN (NERVOUS SYSTEM) CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune booster outsmart brain lymphoma?
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Can a daily pill keep brain lymphoma at bay after remission?